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nonasal SCC (30% of total cost of care). The lifetime
cost of managing annual incident SCCHN cases was esti-
mated to approximate $976 million. CONCLUSION:
This study found that tumor stage and location are useful
predictors of increased treatment costs. The results sug-
gest that prevention and early detection are critical in re-
ducing the treatment costs of SCCHN.
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DETECTING RECURRENT PAPILLARY OR 
FOLLICULAR THYROID CANCER IN 
CLINICALPRACTICE: NEED FOR A CHANGE?
Hooft L, Hoekstra OS
University Hospital Vrije Universiteit, Amsterdam, Netherlands
OBJECTIVES: Patients with thyroid carcinoma (TC) can
present a diagnostic dilemma when elevated tumormark-
ers (thyroglobulin, Tg) suggest relapse but whole body
131-iodine scanning (131I WBS) is negative. Then, bat-
tery of imaging modalities is available. In recent years,
positron emission tomography has been proposed as an
effective and comprehensive staging procedure. To esti-
mate the effort and yield of present clinical practice, we
performed a retrospective study. METHODS: From our
Tg database we identified all TC patients, and included
those with elevated Tg levels (&#61619; 1.5 pmol/l on
thyroid hormone medication) after ablation with 131I,
between 1-5-96 and 1-1-98, and recorded the applied di-
agnostic work-up. RESULTS: Tg data were identified
from 116 patients with TC. Twenty met the inclusion cri-
teria, 18 of which (90%) had a complicated work-up. Re-
current disease was confirmed in 16. The mean number
of imaging tests required to arrive at a clinical conclusion
was 5 (range 3–9), within a mean period of 18 months.
Since 1997, PET has been performed in 15 patients with
negative or equivocal high dose 131I WBS (8 positive and
7 negative scans). Tumor sites first disclosed by PET were
found in 5 patients. CONCLUSIONS: The current diag-
nostic trajectory in the majority of the patients with ele-
vated Tg and negative 131I WBS proved to be protracted
and complicated. Even though prognosis may not neces-
sarily be adversely affected by this delay, patient anxiety
is a considerable problem. FDG-PET may solve clinical
problems in some of these patients, but the currently
available evidence does not allow for implementation of
a routine diagnostic algorithm.
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OBJECTIVES: Since becoming widely recognized for its
antithrombotic effects in the 1970s, aspirin has become
first-line antiplatelet therapy across most patient popula-
tions. However, newer data suggests that clopidogrel is
more effective than aspirin for prevention of ischemic
events in peripheral artery disease (PAD) patients. In this
analysis, a decision analytic model was constructed in or-
der to evaluate the cost-effectiveness of clopidogrel versus
aspirin as prevention of ischemic events in patients with
established PAD. METHODS: Data on the probability of
ischemic events was extracted from the PAD subgroup of
the CAPRIE trial, in which event rates for clopidogrel
and aspirin were 3.71% and 4.86%, respectively. Costs
included in this analysis were obtained from the medical
literature. RESULTS: In the base case analysis, the ex-
pected cost of treatment over a one-year time frame with
clopidogrel and aspirin was $2075 and $1088, respec-
tively. Furthermore, to effectively treat one patient, it
would cost $2155 with clopidogrel and $1144 with aspi-
rin. An incremental cost-effectiveness analysis concluded
that one additional event of vascular death, MI, or
ischemic stroke will be prevented with clopidogrel at an
additional one-year cost of $85,826. A univariate sensi-
tivity analysis demonstrated that aspirin must have ischemic
event rates greater than 13% for clopidogrel to be the
preferred option based solely on cost. Furthermore, in or-
der for clopidogrel to be considered cost-effective with an
event rate of 3.71%, aspirin must have an event rate of
11.48%, a rate 2.4 times greater than was observed in
the CAPRIE trial. CONCLUSIONS: The result of this
analysis concluded that it would cost a third-party payer
an extra $85,826 to effectively treat one additional pa-
tient over a one-year period when using clopidogrel in-
stead of aspirin. This cost can play a major role in the de-
cision of appropriate antiplatelet therapy used to treat
PAD patients in the prevention of ischemic events.
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ECONOMIC CONSEQUENCES IN HOSPITAL
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OBJECTIVES: The risk of VTE disease in patients under-
going major orthopedic surgery (MOS) has extensively
been studied in randomised clinical trials and more re-
cently in cohort studies. Our objective was to estimate
the risk of VTE disease in a much larger population and
to calculate its economic consequences in hospital.
METHODS: We conducted a retrospective study of the
risk of occurrence and associated costs of VTE compli-
cations (including deep vein thrombosis (DVT) and pul-
monary embolism (PE)) in patients undergoing MOS
(including hip replacement, hip fracture and knee re-
placement). Data were obtained from the National inpa-
tient Diagnosis Related Group (DRG) data base with ex-
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haustive information concerning all the patients having
undergone MOS in the year 1998 in France. These pa-
tients were stratified based on the presence or absence of
a listed secondary diagnosis of DVT or PE. Length of stay
in hospital and cost of inpatient care were then compared
between patients with and without secondary diagnosis
of VTE. RESULTS: 105,952 hospital stays, 37,034 and
58,135 were respectively recorded for hip replacement,
knee replacement and hip fracture. Rates of VTE were re-
corded to be 1.4% and 2.6% for hip replacement and
knee replacement respectively. For each primary Diagno-
sis Related Group, the length of stay was shown to be sig-
nificantly higher in case of occurrence of VTE complica-
tions (19.1 days versus 15.1 for hip replacement, 18 days
versus 15.2 for knee replacement, 21.4 days versus 13.8
for hip fracture). Consequently, total costs of inpatient
care were substantially higher for patients with VTE
complications. CONCLUSION: The rates of VTE ob-
served from the National inpatient database provide in-
formation on the frequency of VTE complications after
MOS in real setting. In patients undergoing major ortho-
pedic surgery, the occurrence of VTE is associated with a
longer hospital stay and higher cost of inpatient care.
PCV3
AN ANALYSIS OF THE COST OF ADVERSE 
EVENTS ASSOCIATED WITH THE USE OF
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OBJECTIVE: To perform an analysis of the cost of ad-
verse events (AEs) associated with treatment by atorva-
statin, fluvastatin, lovastatin, pravastatin, and simvasta-
tin following NCEP low density lipoprotein-cholesterol
(LDL-C) guidelines. METHODS: Data come from a 54-
week randomized, open-label, double-blind controlled
trial conducted in 158 US centers between May 1997 and
January 1999. Patients (n  3916) with or without coro-
nary heart disease and/or peripheral vascular disease
were randomized to receive atorvastatin (n  1958), flu-
vastatin (n  497), lovastatin (n  498), pravastatin (n 
481), and simvastatin (n  482). Inclusion criteria in-
cluded elevated LDL-C for patients 18–80 years of age.
Exclusion criteria included known hypersensitivity to
HMG-CoA reductase inhibitors, use of selected medica-
tions, and other patient characteristics. Data were col-
lected on AEs. RESULTS: A total of 9707 AEs were re-
ported during the trial. Of these AEs, 1327 (14%) were
related to the use of study medications. Related AEs in-
volved the digestive system (387, 29%), musculoskeletal
system (356, 27%), central nervous system (269, 20%),
skin (124, 9%), abnormal laboratory values (68, 5%),
respiratory system (40, 3%), urogenital system (25, 2%),
cardiovascular system (24, 2%), and miscellaneous (35,
3%). The 1327 medication related AEs were associated
with the use of 1384 medical services. Many AEs were
treated at scheduled study visits (239, 18%) and did not
involve additional costs. Additional medical services typi-
cally consisted of physician office visits. There was one
hospitalization (gastroenteritis). Costs of AEs were mea-
sured at Medicare payment rates—a third party perspec-
tive. The average cost of treating AEs were similar among
study arms: atorvastatin $27.78, fluvastatin $31.78, lov-
astatin $26.58, pravastatin $25.17, and simvastatin
$32.58 (no differences were significant at p  0.1).
CONCLUSIONS: Results suggest that the cost associated
with adverse events related to study medications did not
vary significantly among HMG-CoA reductase inhibitors
used to treat patients with elevated cholesterol levels.
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ASSESSING QUALITY OF LIFE IN PATIENTS SIX 
MONTHS AFTER A MYOCARDIAL INFARCTION 
USING THE SF-12
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OBJECTIVES: To assess patients’ quality of life (HQL)
post-myocardial infarction and to identify related vari-
ables. METHODS: Patients admitted to the University of
Michigan Medical Center with diagnosis of MI were
identified consecutively and prospectively from October
1999 to May 2000. Clinical data were obtained retro-
spectively from medical records. Six months after dis-
charge, patients were administered the Short Form-12
(SF-12), via telephone, to determine physical (PCS-12)
and mental (MCS-12) functional status. RESULTS:
Complete information was obtained from 148 patients.
The mean age of patients was 64.7 years (13.2) and
79.1% were male. The mean PCS-12 scores were 35.4
(9.12), and the mean MCS-12 scores were 51.6
(10.01). The median PCS-12 scores were significantly
lower in patients with an ejection fraction (EF) 40%
(31.9 versus 38.4 for EF340%, p  0.02), and prior MI
(31.2 versus 38.5 without a history of MI, p  0.01),
congestive heart failure (CHF) (32.6 versus 37.4 without
a history of CHF, p  0.03), renal insufficiency (27.9
versus 37.7, p  0.003), or peripheral vascular disease
(29.4 versus 38.2 without a history of PVD, p  0.004).
The median MCS-12 scores were significantly lower for
patients under 65 years of age (49.6 versus 57.4 for pa-
tients 365 years of age, p  0.001) and with a history of
coronary artery bypass graft (CABG) (60.1 versus 54.7
without history of CABG, p  0.01). There were no dif-
ferences detected between gender, type of MI, diabetes,
hypertension, angina, or smoking. CONCLUSIONS: HQL
scores were lower for patients post-MI with various co-
morbidities. Physical scores were significantly lower for
patients with low EFs, prior MI, or CHF. Mental scores
were significantly lower for patients 65 and those not
having already undergone CABG surgery. Post-MI, par-
ticular attention should be paid to these patients. Further
